Licensing & partnership

SRX Updates T-Cell Strategy

SRX highlighted Pfizer's $330 million upfront licensing agreement with Starna as evidence of interest in engineered T-cell platforms, while noting that the deal is not a valuation benchmark for CERo. CERo has dosed seven patients in its ongoing Phase 1/1b CERTAIN-T trial of CER-1236; no dose-limiting toxicities were reported during assessment of the first three patients in the second cohort.

SRX's proposed acquisition of CERo Therapeutics remains pending. The clinical findings are preliminary and do not establish CER-1236's safety or efficacy.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call